{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:07:52Z","timestamp":1788772072517,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["20H05675"],"award-info":[{"award-number":["20H05675"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["23H02765"],"award-info":[{"award-number":["23H02765"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["24H00804"],"award-info":[{"award-number":["24H00804"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["25H00006"],"award-info":[{"award-number":["25H00006"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"JST ERATO","doi-asserted-by":"publisher","award":["JPMJER2102"],"award-info":[{"award-number":["JPMJER2102"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP23ym0126809"],"award-info":[{"award-number":["JP23ym0126809"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["25ym0126144h0002"],"award-info":[{"award-number":["25ym0126144h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS Fellows","doi-asserted-by":"publisher","award":["22J10766"],"award-info":[{"award-number":["22J10766"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS Grant-in-Aid for Transformative Research Areas","doi-asserted-by":"publisher","award":["22H04924"],"award-info":[{"award-number":["22H04924"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Peritoneal dissemination of malignancies leads to poor prognoses, and no effective treatment currently exists. The difficulty of treating such malignancies is likely because systemically administered drugs cannot easily target malignant cells in the abdominal cavity. High intraperitoneal drug retention, non-toxicity towards normal tissues, and successful targeting of malignant cells are important for an effective therapy. The aim of this study was to evaluate an intraperitoneally administered astatine-labeled, integrin-targeted nanodrug, mPEG(Mn:350)-S-AuNP[211At]-c[RGDfK(C)] ([211At]AuNP@PEG\/RGD), with respect to its kinetics, therapeutic efficacy, and safety. Methods: C6 rat glioma cells (107), and BxPC3 (107) and PANC-1 (107) human pancreatic cancer cells were seeded intraperitoneally into nude mice, and [211At]AuNP@PEG\/RGD (0.979 \u00b1 0.194 MBq for C6 models (n = 3), 1.139 \u00b1 0.035 MBq for BxPC3 models (n = 10), and 1.308 \u00b1 0.039 MBq for PANC-1 models (n = 10) per mouse) or saline were intraperitoneally administered 4\u20137 days later. Cytotoxicity against malignant cells, pharmacokinetics after administration, therapeutic efficacy, and safety in abdominal organs were evaluated. Results: Intraperitoneally administered [211At]AuNP@PEG\/RGD accumulated exclusively in the peritoneal cavity for a long period of time and showed minimal systemic diffusion through the blood. In the C6 model, the intraperitoneal tumor mass was significantly lower in the treated group compared with that of the controls (p = 0.05). For the BxPC3 (median survival time: control\/treated = 41\/65 days, p &lt; 0.001) and PANC-1 (median survival time: control\/treated = 19\/35 days, p &lt; 0.001) peritoneal dissemination models, survival analysis revealed that [211At]AuNP@PEG\/RGD significantly prolonged overall survival. Although transient weight loss, leukopenia, and thrombocytopenia were observed at one week post-administration, a short recovery trend was evident thereafter. One month after administration, no abnormalities were found in hematological tests or histological analyses of intra-abdominal organs. Conclusions: The intraperitoneal administration of astatine-labeled integrin-targeted [211At]AuNP@PEG\/RGD nanoparticles showed promising findings in terms of safety and efficacy for treating peritoneally disseminated malignant tumors.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091102","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:56:01Z","timestamp":1788339361000},"page":"1102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Efficacy and Safety of Intraperitoneally Administered 211At-Labeled Gold Nanoparticles for Peritoneally Disseminated Malignancies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0838-6772","authenticated-orcid":false,"given":"Hiroki","family":"Kato","sequence":"first","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0342-1292","authenticated-orcid":false,"given":"Xuhao","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Erina","family":"Hilmayanti","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Graduate School of Science, The University of Osaka, Toyonaka 560-0043, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Yuichiro","family":"Kadonaga","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-027X","authenticated-orcid":false,"given":"Kazuhiro","family":"Ooe","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-2263","authenticated-orcid":false,"given":"Masashi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"given":"Kazuya","family":"Kabayama","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-5059","authenticated-orcid":false,"given":"Kazuko","family":"Kaneda-Nakashima","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"given":"Atsushi","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"given":"Xiaojie","family":"Yin","sequence":"additional","affiliation":[{"name":"Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-8305","authenticated-orcid":false,"given":"Hiromitsu","family":"Haba","sequence":"additional","affiliation":[{"name":"Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"given":"Koichi","family":"Fukase","sequence":"additional","affiliation":[{"name":"Institute for Radiation Sciences, The University of Osaka, 2-4, Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","article-title":"Peritoneal carcinomatosis","volume":"19","author":"Coccolini","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPA.0000000000000290","article-title":"Pancreatic cancer with malignant ascites: Clinical features and outcomes","volume":"44","author":"Takahara","year":"2015","journal-title":"Pancreas"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","article-title":"Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study","volume":"42","author":"Thomassen","year":"2013","journal-title":"Pancreas"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12957-016-0767-y","article-title":"A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma","volume":"14","author":"Satoi","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Simon-Gracia, L., Hunt, H., and Teesalu, T. (2018). Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides. Molecules, 23.","DOI":"10.20944\/preprints201804.0254.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/fon.10.100","article-title":"Intraperitoneal therapy for peritoneal cancer","volume":"6","author":"Lu","year":"2010","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Huq, M.A., Rana, M.R., Samad, A., Rahman, M.S., Rahman, M.M., Ashrafudoulla, M., Akter, S., and Park, J.W. (2025). Green Synthesis, Characterization, and Potential Antibacterial and Anticancer Applications of Gold Nanoparticles: Current Status and Future Prospects. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051184"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12951-021-00963-9","article-title":"Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy","volume":"19","author":"Kato","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: Bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11307-022-01704-6","article-title":"Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer","volume":"24","author":"Sun","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/bjc.2016.312","article-title":"The complexity of integrins in cancer and new scopes for therapeutic targeting","volume":"115","author":"Hamidi","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10555-020-09924-4","article-title":"Molecular mediators of peritoneal metastasis in pancreatic cancer","volume":"39","author":"Avula","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13046-021-01946-2","article-title":"Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression","volume":"40","author":"Kemper","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/00006676-200208000-00021","article-title":"Expression of integrin \u03b1v\u03b23 in pancreatic carcinoma: Relation to MMP-2 activation and lymph node metastasis","volume":"25","author":"Hosotani","year":"2002","journal-title":"Pancreas"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1878-0261.12845","article-title":"Constitutive activation of integrin \u03b1v\u03b23 contributes to anoikis resistance of ovarian cancer cells","volume":"15","author":"Dolinschek","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/path.5320","article-title":"The integrin alphavbeta6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy","volume":"249","author":"Reader","year":"2019","journal-title":"J. Pathol."},{"key":"ref_22","first-page":"909","article-title":"Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma","volume":"24","author":"Bergmann","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2174\/1381612822666151209153636","article-title":"RGD-based Therapy: Principles of Selectivity","volume":"22","author":"Rubtsov","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bbcan.2018.04.005","article-title":"RGD cadherins and alpha2beta1 integrin in cancer metastasis: A dangerous liaison","volume":"1869","author":"Casal","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e6800","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.F., Goebel, M., Hein, R., and Wester, H.J. (2005). Noninvasive visualization of the activated \u03b1v\u03b23 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020070"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00259-014-2791-x","article-title":"[18F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing \u03b1v\u03b23 and \u03b1v\u03b25 integrins","volume":"41","author":"Mena","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.107.047423","article-title":"Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice","volume":"49","author":"Jeong","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1166\/jbn.2014.1721","article-title":"Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice","volume":"10","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100757","DOI":"10.1016\/j.tranon.2020.100757","article-title":"Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [211At] NaAt in Mice: A Revisit","volume":"13","author":"Liu","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_32","first-page":"H26","article-title":"Peritoneal absorption of macromolecules studied by quantitative autoradiography","volume":"248","author":"Flessner","year":"1985","journal-title":"Am. J. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.2600740902","article-title":"Lymphatic transport of liposome-encapsulated agents: Effects of liposome size following intraperitoneal administration","volume":"74","author":"Hirano","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12094-007-0083-7","article-title":"Update in the management of ovarian and cervical carcinoma","volume":"9","author":"Poveda","year":"2007","journal-title":"Clin. Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1177\/089686089301302S09","article-title":"A three-pore model of peritoneal transport","volume":"13","author":"Rippe","year":"1993","journal-title":"Perit. Dial. Int."},{"key":"ref_36","first-page":"189","article-title":"Lymphatic versus nonlymphatic fluid absorption from the peritoneal cavity as related to the peritoneal ultrafiltration capacity and sieving properties","volume":"10","author":"Rippe","year":"1992","journal-title":"Blood Purif."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"F781","DOI":"10.1152\/ajprenal.00621.2012","article-title":"Quantification of the electrostatic properties of the glomerular filtration barrier modeled as a charged fiber matrix separating anionic from neutral Ficoll","volume":"304","author":"Oberg","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Albertsson, P., Back, T., Bergmark, K., Hallqvist, A., Johansson, M., Aneheim, E., Lindegren, S., Timperanza, C., Smerud, K., and Palm, S. (2022). Astatine-211 based radionuclide therapy: Current clinical trial landscape. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1076210"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jnr.490310309","article-title":"Expression of multiple integrins and extracellular matrix components by C6 glioma cells","volume":"31","author":"Rome","year":"1992","journal-title":"J. Neurosci. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1593\/tlo.11133","article-title":"Role of \u03b15\u03b21 Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells","volume":"4","author":"Yao","year":"2011","journal-title":"Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/1389200216666150223152958","article-title":"Advances and challenges in the use of nanoparticles to optimize PK\/PD interactions of combined anti-cancer therapies","volume":"15","author":"Liu","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.0803728105","article-title":"Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis","volume":"105","author":"Murphy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ijc.22297","article-title":"\u03b1v\u03b23 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide","volume":"120","author":"Dijkgraaf","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wang, L., Fan, J., Chen, X., Lei, W., Jiang, C., Liu, H., Yang, Y., and Shen, J. (2024). An investigation into the correlation between intraperitoneal teicoplanin concentrations and treatment outcomes in peritoneal dialysis-associated peritonitis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1446774"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:10:18Z","timestamp":1788768618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091102"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091102","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}